New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
Goff
Donald C
DC
D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D000068180:Aripiprazole; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D011788:Quality of Life / Q000523:psychology*; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013997:Time Factors
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017448:Receptors, Dopamine D2; D000068180:Aripiprazole